High Growth Tech Stocks To Watch In The United States

Over the last 7 days, the market has remained flat, but it is up 23% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks that align with these optimistic projections can be crucial for investors seeking robust returns.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	28.62%	43.05%	★★★★★★
Sarepta Therapeutics	24.22%	44.94%	★★★★★★
Super Micro Computer	20.62%	27.13%	★★★★★★
Ardelyx	27.44%	65.50%	★★★★★★
G1 Therapeutics	27.57%	57.75%	★★★★★★
Invivyd	42.91%	70.39%	★★★★★★
Amicus Therapeutics	20.45%	61.85%	★★★★★★
Clene	73.06%	62.58%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Appian (NasdaqGM:APPN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Appian Corporation is a software company that offers a low-code design platform across the United States, Mexico, Portugal, and internationally, with a market cap of $2.35 billion.

Operations: Appian Corporation generates revenue primarily from its software and programming segment, amounting to $578.70 million. The company operates internationally, including in the United States, Mexico, and Portugal.

Appian's strategic focus on process automation and low-code development is driving notable partnerships and client adoptions, such as the collaboration with Outsourcing Technology Co. Ltd. in Japan, which reduced workload by 25%. Revenue for Q2 2024 reached $146.45 million, a 14.65% increase from the previous year, despite a net loss of $43.59 million. The company’s R&D expenses have been significant; in the last fiscal year alone, Appian invested approximately $100 million to enhance its platform capabilities. Software firms are increasingly moving to SaaS models, ensuring recurring revenue from subscriptions; Appian's AI Process Platform exemplifies this trend by offering integrated solutions like the Victorian Office of Public Prosecutions' new matter management system that anticipates a productivity gain of over 10% annually. Future prospects appear promising with forecasted annual revenue growth at 10.3%, outpacing the broader US market's expected growth rate of 8.7%.

• Click to explore a detailed breakdown of our findings in Appian's health report.

• Explore historical data to track Appian's performance over time in our Past section.

Amicus Therapeutics (NasdaqGM:FOLD)

Simply Wall St Growth Rating: ★★★★★★

Overview: Amicus Therapeutics, Inc. is a biotechnology company dedicated to discovering, developing, and delivering medicines for rare diseases with a market cap of $3.44 billion.

Operations: Amicus Therapeutics focuses on the discovery, development, and commercialization of advanced therapies for rare diseases, generating $455.66 million in revenue. The company operates within the biotechnology sector with a market cap of approximately $3.44 billion.

Amicus Therapeutics’ revenue is forecast to grow at 20.4% annually, outpacing the broader US market's 8.7%. The company reported a net loss of $15.7 million for Q2 2024, a significant improvement from the $43.23 million loss a year ago, reflecting strategic cost management and operational efficiencies. With R&D expenses constituting a substantial part of their budget, Amicus invested heavily in innovation to drive future growth, contributing to an expected annual earnings growth rate of 61.85%.

• Take a closer look at Amicus Therapeutics' potential here in our health report.

• Gain insights into Amicus Therapeutics' historical performance by reviewing our past performance report.

TKO Group Holdings (NYSE:TKO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: TKO Group Holdings, Inc. operates as a sports and entertainment company with a market cap of $20.17 billion.

Operations: TKO Group Holdings generates revenue primarily through its UFC segment, which reported $1.39 billion. The company also includes a significant segment adjustment of $1.16 billion in its financials.

TKO Group Holdings has shown significant revenue growth, with a 179% increase to $851.16 million in Q2 2024 compared to the prior year's $305.2 million. Despite a net income drop from $81.4 million to $59.11 million, the company raised its full-year revenue guidance to between $2.67 billion and $2.745 billion, reflecting strong performance expectations for the latter half of 2024. R&D expenses are notable; they constitute a substantial part of their budget as they drive innovation and future growth in the competitive tech landscape. The company repurchased 1,853,724 shares for $165 million between April 7-10, demonstrating confidence in its valuation and financial health despite recent auditor changes from Deloitte to KPMG due to regulatory implications tied to an acquisition by Silver Lake. Earnings are forecasted to grow at an impressive annual rate of 66%, underpinned by strategic investments and operational efficiencies that could position TKO favorably within high-growth tech sectors moving forward.

• Unlock comprehensive insights into our analysis of TKO Group Holdings stock in this health report.

• Gain insights into TKO Group Holdings' past trends and performance with our Past report.

Turning Ideas Into Actions

• Explore the 249 names from our US High Growth Tech and AI Stocks screener here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com